Literature DB >> 277266

Platinum complexes as radiosensitizers of hypoxic mammalian cells.

E B Douple, R C Richmond.   

Abstract

Cis-dichlorodiammineplatinum (II), or cis-PDD, has recently been shown to be a potent radiosensitizer of bacteria, particularly under conditions of acute hypoxia. This study extends this observation to include the radiosensitization of mammalian cell (V-79) by low concentrations of cis-PDD, cis-dichlorobis(aziridine) platinum (II), and the trans-isomer of PDD as measured from survival curve analysis. This radiosensitization was obtained at concentrations of 10 micrometer, 60 micrometer, and 100 micrometer for the cis-PDD, aziridine-platinum, and trans-isomer respectively. The corresponding drug toxicity survival levels were 8, 40 and 50%. Dose modification factors of around 1.3 to 1.4 were observed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 277266      PMCID: PMC2149376     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  8 in total

1.  An analysis of the interaction of a platinum complex and radiation with CHO cells using the molecular theory of cell survival.

Authors:  K H Chadwick; H P Leenhouts; I Szumiel; A H Nias
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1976-12

2.  Radiation-induced DNA damage and lethality in E. coli as modified by the antitumor agent cis-dichlorodiammineplatinum (II).

Authors:  R C Richmond; J D Zimbrick; D L Hykes
Journal:  Radiat Res       Date:  1977-08       Impact factor: 2.841

3.  Combination radiotherapy and chemotherapy for P388 lymphocytic leukemia in vivo.

Authors:  I Wodinsky; J Swiniarski; C J Kensler; J M Venditti
Journal:  Cancer Chemother Rep 2       Date:  1974-03

4.  New platinum complexes with anti-tumour activity.

Authors:  T A Connors; M Jones; W C Ross; P D Braddock; A R Khokhar; M L Tobe
Journal:  Chem Biol Interact       Date:  1972-11       Impact factor: 5.192

5.  The effect of extreme hypoxia on recovery after radiation by synchronized mammalian cells.

Authors:  C J Koch; J Kruuv
Journal:  Radiat Res       Date:  1971-10       Impact factor: 2.841

6.  Radiation sensitization of bacterial spores by cis-dichlorodiammineplatinum(II).

Authors:  R C Richmond; E L Powers
Journal:  Radiat Res       Date:  1976-11       Impact factor: 2.841

Review 7.  Platinum coordination complexes in cancer chemotherapy.

Authors:  B Rosenberg
Journal:  Naturwissenschaften       Date:  1973-09

8.  The effect of combined treatment with a platinum complex and ionizing radiation on chinese hamster ovary cells in vitro.

Authors:  I Szumiel; A H Nias
Journal:  Br J Cancer       Date:  1976-04       Impact factor: 7.640

  8 in total
  12 in total

1.  Targeted infusions of supradose Cisplatin with systemic neutralization for carcinomas invading the temporal bone.

Authors:  K T Robbins; P K Pelliteri; D Vicario; C W Kerber; J H Robertson; C Hanchett; S B Howell
Journal:  Skull Base Surg       Date:  1996

2.  Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas.

Authors:  D J Stewart; S Dahrouge; O Agboola; A Girard
Journal:  J Neurooncol       Date:  1997-04       Impact factor: 4.130

3.  Energy-dispersive X-ray fluorescence determination of platinum in plasma, urine, and cerebrospinal fluid of patients administered cis-dichlorodiammineplatinum(II).

Authors:  W E Seifert; D J Stewart; R S Benjamin; R M Caprioli
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain.

Authors:  D J Stewart; L G Feun; M Maor; M Leavens; M A Burgess; R S Benjamin; G P Bodey
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

5.  Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.

Authors:  Nancy Lee; Sadek Nehmeh; Heiko Schöder; Matthew Fury; Kelvin Chan; C Clifton Ling; John Humm
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-07       Impact factor: 7.038

6.  Human tissue distribution of platinum after cis-diamminedichloroplatinum.

Authors:  D J Stewart; R S Benjamin; M Luna; L Feun; R Caprioli; W Seifert; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

7.  External beam radiation plus concurrent intra-arterial chemotherapy with low dose cisplatin for muscle invasive bladder cancer.

Authors:  Yoshihiro Matsumoto; Shoji Samma; Shinji Fukui; Yasushi Nakai; Yoriaki Kagebayashi; Kazumasa Torimoto
Journal:  Indian J Urol       Date:  2015 Jan-Mar

8.  Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer.

Authors:  Jun-Ichi Saitoh; Katsuyuki Shirai; Masumi Imaeda; Atsushi Musha; Takanori Abe; Masato Shino; Yukihiro Takayasu; Katsumasa Takahashi; Kazuaki Chikamatsu; Takashi Nakano
Journal:  Radiat Oncol       Date:  2017-02-20       Impact factor: 3.481

9.  Enhancing radiotherapy by lipid nanocapsule-mediated delivery of amphiphilic gold nanoparticles to intracellular membranes.

Authors:  Yu-Sang Yang; Randy P Carney; Francesco Stellacci; Darrell J Irvine
Journal:  ACS Nano       Date:  2014-08-20       Impact factor: 15.881

10.  Interactions of radiation and adriamycin, bleomycin, mitomycin C or cis-diamminedichloroplatinum II in intestinal crypt cells.

Authors:  H von der Maase
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.